Avidea’s polymer-drug conjugate (PDC) platforms overcome key hurdles for enabling successful immunotherapies. Learn more
Our team is building on more than two decades of pioneering work by our world-class scientific founders and advisors who are experts in immunology, oncology, vaccines and biomaterials.About us
Avidea is looking for highly motivated and talented individuals to join our team. Check out our careers page to learn about opportunities to join our growing team.Join us
Scientific principles underlying technology platforms
In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.
Description of SNAPvax as a platform for promoting T cell immunity
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
Immunological mechanisms for enhanced efficacy by intravenous vaccination
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.
Avidea Technologies and University of Maryland Awarded Grant to Evaluate Avidea’s SNAPvaxTM Tolerance Vaccine (TV) for Treating Autoimmune Diseases
Avidea Technologies and Collaborators Publish Results in Nature Immunology Showing SNAPvaxTM Cancer Vaccine Administered IV Generates Stem-Like (TCF1+) Neoantigen-Sepcific CD8+ T cells Resulting in Improved Efficacy
Nature Biotechnology features Avidea’s self-assembling nanoparticle technology, SNAPvax (SNP-7/8a) on the Cover of its March 2020 issue